Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dose-response relationships in determining the safety:efficacy ratio

A Leff1

  • 1Department of Medicine, University of Chicago, IL 60637, USA.

Respiratory Medicine
|February 25, 1998
PubMed
Summary

New inhaled asthma medications, including long-acting beta 2-agonists and potent corticosteroids, offer improved safety and effectiveness. Metered dose inhaler use does not independently increase asthma fatality risk.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Paraneoplastic "stiff person syndrome" with metastatic adenocarcinoma and anti-Ri antibodies.

Neurology·2004
Same author

Clean round the bend - the etymology of jargon and slang terms for madness.

History of psychiatry·2001
Same author

Identification of higher brain centres that may encode the cardiorespiratory response to exercise in humans.

The Journal of physiology·2001
Same author

Noun imageability and the temporal lobes.

Neuropsychologia·2000
Same author

Outcomes after long-term acute care. An analysis of 133 mechanically ventilated patients.

American journal of respiratory and critical care medicine·1999
Same author

Outcomes and resource utilization for patients with prolonged critical illness managed by university-based or community-based subspecialists.

American journal of respiratory and critical care medicine·1998

Area of Science:

  • Pulmonology and Pharmacology

Background:

  • Asthma treatment has advanced with inhaled medications.
  • Selective beta 2-adrenoceptor agonists and high-potency corticosteroids improve drug delivery.
  • This targeted delivery minimizes systemic exposure and adverse events.

Purpose of the Study:

  • To review the advancements in inhaled asthma therapies.
  • To highlight the improved toxicity: therapeutic ratios of new medications.
  • To discuss the value of these treatments in preventing severe asthma exacerbations.

Main Methods:

  • Review of current pharmacological treatments for asthma.
  • Analysis of drug delivery mechanisms and their impact on systemic exposure.
  • Examination of risk factors for fatal and near-fatal asthma.

Main Results:

  • Inhaled long-acting beta 2-agonists (e.g., salmeterol, formoterol) and high-efficacy corticosteroids (e.g., fluticasone propionate, budesonide) are clinically available.
  • These agents offer improved toxicity: therapeutic ratios.
  • Suboptimal asthma treatment is linked to increased morbidity, mortality, and societal costs.

Conclusions:

  • Modern inhaled therapies represent significant progress in asthma management.
  • Effective asthma treatment is crucial for reducing patient morbidity and healthcare costs.
  • Metered dose inhaler administration is not an independent risk factor for asthma fatalities.

Related Experiment Videos